Signaling Pathways in Leukemia: Any Role for Medicinal Plants in Leukemia Therapy
Journal of Diseases and Medicinal Plants
Volume 1, Issue 5, December 2015, Pages: 76-79
Received: Dec. 13, 2015; Accepted: Dec. 23, 2015; Published: Jan. 23, 2016
Views 3702      Downloads 153
Authors
Paul Takam Kamga, Department of Medicine, Section of Hematology, Stem Cell Research Laboratory, University of Verona, 37129, Verona, Italy
Armel Herve Nwabo Kamdje, Department of Biomedical Sciences, Faculty of Sciences, University of Ngaoundere, Ngaoundere, Cameroon
Article Tools
Follow on us
Abstract
Leukemia is a cancer of the early blood-forming cells. Most often, leukemia is a cancer of the white blood cells, but some leukemias start in other blood cell types. Scientists in the U.S. believe they have identified a new pathway in the progression of chronic myelogenous leukemia (CML). They have also discovered that an extract from the root of a common ornamental plant can suppress the process. Drug discovery from natural sources involve a multifaceted approach combining botanical, phytochemical, biological, and molecular techniques. Accordingly, medicinal-plant-based drug discovery still remains an important area, hitherto unexplored, where a systematic search may definitely provide important leads against various pharmacological targets. Ironically, the potential benefits of plant-based medicines have led to unscientific exploitation of the natural resources, a phenomenon that is being observed globally. This decline in biodiversity is largely the result of the rise in the global population, rapid and sometimes unplanned industrialization, indiscriminate deforestation, and overexploitation of natural resources, pollution, and finally global climate change. Therefore, it is of utmost importance that plant biodiversity be preserved, to provide future structural diversity and lead compounds for the sustainable development of human civilization at large. This becomes even more important for developing nations, where well-planned bioprospecting coupled with nondestructive commercialization could help in the conservation of biodiversity, ultimately benefiting mankind in the long run. Based on these findings, the present review is an attempt to update our knowledge about the role of signaling pathways and medicinal plants in Leukemia therapy.
Keywords
Leukemia, Signaling Pathways, Medicinal Plants, Therapy
To cite this article
Paul Takam Kamga, Armel Herve Nwabo Kamdje, Signaling Pathways in Leukemia: Any Role for Medicinal Plants in Leukemia Therapy, Journal of Diseases and Medicinal Plants. Vol. 1, No. 5, 2015, pp. 76-79. doi: 10.11648/j.jdmp.20150105.12
Copyright
Copyright © 2015 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
H. Clevers, Wnt/beta-catenin signaling in development and disease, Cell 127 (2006) pp. 469-480.
[2]
A. H. Nwabo Kamdje, P. F. Seke Etet, L. Vecchio, J. M. Muller, M. Krampera, K. E. Lukong, Signaling pathways in breast cancer: therapeutic targeting of the microenvironment, Cell Signal. 26 (2014) pp. 2843-2856.
[3]
P. F. Seke Etet, L. Vecchio, A. H. Nwabo Kamdje, Interactions between bone marrow stromal microenvironment and B-chronic lymphocytic leukemia cells: any role for Notch, Wnt and Hh signaling pathways? Cell Signal. 24 (2012) pp. 1433-1443.
[4]
M. T. Chung, H. C. Lai, H. K. Sytwu, M. D. Yan, Y. L. Shih, C. C. Chang, M. H. Yu, H. S. Liu, D. W. Chu, Y. W. Lin, SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway, Gynecol. Oncol. 112 (2009) pp. 646-653.
[5]
C. H. Lin, Y. Guo, S. Ghaffar, P. McQueen, J. Pourmorady, A. Christ, K. Rooney, T. Ji, R. Eskander, X. Zi, B. H. Hoang, Dkk-3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma, Sarcoma. 2013 (2013) p. 147541.
[6]
L. Vecchio, P. F. Seke Etet, M. J. Kipanyula, M. Krampera, A. H. Nwabo Kamdje, Importance of epigenetic changes in cancer etiology, pathogenesis, clinical profiling, and treatment: what can be learned from hematologic malignancies?, Biochim. Biophys. Acta 1836 (2013) pp. 90-104.
[7]
S. Shao, X. Zhao, X. Zhang, M. Luo, X. Zuo, S. Huang, Y. Wang, S. Gu, X. Zhao, Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner, Mol. Cancer 14 (2015) p. 28.
[8]
P. J. Bhavsar, E. Infante, A. Khwaja, A. J. Ridley, Analysis of Rho GTPase expression in T-ALL identifies RhoU as a target for Notch involved in T-ALL cell migration, Oncogene 32 (2013) pp. 198-208.
[9]
Sophia X. Pfister, Enni Markkanen, Yanyan Jiang, Sovan Sarkar, et al. Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation. Cancer Cell. Vol. 28 Iss. 5, November 9, 2015.
[10]
University of Texas M. D. Anderson Cancer Center.
[11]
Rockefeller University.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186